Positive clinical trial results are a strong indicator of a product's efficacy and market potential. For Nexalin Technology, the successful outcomes of its Gen-2 tACS device study in treating chronic insomnia could lead to increased investor confidence, potentially driving up the stock price. The significance of these results lies in the large market demand for effective insomnia treatments, positioning Nexalin to capitalize on this opportunity.